← All trials
NCT05586763
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2022
- Primary completion
- Feb 28, 2023
- Completion date
- Aug 30, 2023
- First posted
- Oct 19, 2022
- Last posted
- Oct 19, 2022
- Enrollment
- 90
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Oman Medical Board Specialty (OMSB)Lead sponsor
- Oman Medical Board Specialty (OMSB)Overall official - principal investigator
- Oman Medical Board Specialty (OMSB)Reponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.